PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and RxCelerate, a leading international out-sourced drug discovery and development service provider, today announced the successful completion of a collaboration to assess small molecules identified from an initial cheminformatics drug screen in a bespoke cell-based assay developed by RxCelerate on one of PlaqueTec’s targets discovered in pilot studies. Identification of suitable candidates from an initial virtual drug screen against a novel target in CAD, discovered by PlaqueTec, formed the basis for the collaboration with RxCelerate. The collaborative project was aimed at assessing the small molecules in a functional cell-based assay offered through RxCelerate’s bespoke services.
The project has enabled the lead compounds to be characterised successfully, demonstrating the value of the assay in the progress of PlaqueTec’s mission to endotype CAD and develop personalised interventions to transform patient care. If the target is validated in PlaqueTec’s ongoing BIOPATTERN trial, the collaborators plan to bring forward other lead compounds for further investigation, alongside further drug screening for other new targets identified and validated in BIOPATTERN. The collaboration between PlaqueTec and RxCelerate was a continuation of an initial pilot project carried out with Medicines Discovery Catapult.
The early project was aimed at using comput.